Results 101 to 110 of about 4,214,171 (152)

Beyond [¹⁷⁷Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents. [PDF]

BMC Cancer
Abdlkadir AS, Al-Adhami D, Moghrabi S, Sathekge MM, Kreissl M, Estrada-Lobato E, Shi H, Al-Ibraheem A.   +7 more
europepmc   +1 more source

Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy. [PDF]

Theranostics
Gustafsson A, Mortensen ACL, Rondahl V, Xu T, Bratteby K, Bernhardt P, Nestor M.   +6 more
europepmc   +1 more source

Preclinical Evaluation of 5T4-Targeted [⁸⁹Zr]Zr-DFO-HB5 Immuno-PET Imaging and Comparison of ¹⁶¹Tb vs ¹⁷⁷Lu Radionuclide Therapy for Colorectal Cancer. [PDF]

J Med Chem
Liang Y, Li X, Liang H, Wu T, Huang Y, Liu S, Yang X, Luo R, Ma F, Huang Y, Li X, Zhou Y.   +11 more
europepmc   +1 more source

Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy. [PDF]

Clin J Oncol Nurs
Davis ME, Longing A.
europepmc   +1 more source

Low Radioactivity Levels in Blood Samples After Targeted Radionuclide Therapy: Minimal Radiation Exposure of Healthcare Staff. [PDF]

Biomedicines
Wehmann M, Seifert P, Kühnel C, Drescher R, Gühne F, Freesmeyer M.   +5 more
europepmc   +1 more source

A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti-PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer. [PDF]

Clin Cancer Res
Tagawa ST, Thomas C, Arham AB, Holmes A, Marulanda Corzo V, Okobi T, Vallabhajosula S, Avlonitis V, Huicochea Castellanos S, Nauseef JT, O'Dwyer E, Fatima M, Gregos P, Yuan S, Sternberg CN, Molina A, Nanus DM, Bander NH, Osborne JR.   +18 more
europepmc   +1 more source

Innovative radiotherapies for the treatment of glioblastoma. [PDF]

Neurooncol Adv
Van Eupen L, Waked A, Primac I, Vermeulen K, De Bie I, Benotmane MA, Quintens R.   +6 more
europepmc   +1 more source

Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling. [PDF]

Pharmaceutics
Ha S, O JH, Park C, Boo SH, Shin D, Moon HW, Yoo IR, Kim IH, Lee JY.   +8 more
europepmc   +1 more source

Predicting tumour and organ dose in α-radiopharmaceutical therapy: a ⁸⁹Zr-based dosimetric approach for ²²⁵Ac. [PDF]

Eur J Nucl Med Mol Imaging
Merkx RIJ, Kleinendorst SC, Rijpkema M, Franssen GM, Morgenstern A, Bruchertseifer F, Wheatcroft MP, Oosterwijk E, Mulders PFA, Konijnenberg M, Heskamp S.   +10 more
europepmc   +1 more source

Theranostic Imaging Agents: Integrating Molecular Diagnostics, Precision Therapeutics, and Artificial Intelligence. [PDF]

Biomolecules
Sharma S, Rabbani SA, El-Tanani M, Patni MM, Kumar R, Saini M.   +5 more
europepmc   +1 more source